Welcome to our dedicated page for BioCardia SEC filings (Ticker: BCDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioCardia, Inc. SEC filings document a clinical-stage biotechnology and medical-device business focused on cell therapies and related delivery technologies for cardiovascular and pulmonary disease. Recent Form 8-K reports cover Regulation FD disclosures and other events involving CardiAMP clinical data, FDA and PMDA regulatory interactions, the Helix transendocardial delivery catheter, and patent protection for Heart3D Fusion Imaging software.
The company’s filings also record annual operating results, research and development activity, liquidity-related financial disclosures, and Nasdaq continued-listing compliance matters. These documents frame BCDA’s public-company record around product-development programs, regulatory pathways, intellectual property, capital and listing status, risk disclosures, and corporate reporting obligations.
BioCardia, Inc. (BCDA) reports that Nasdaq has notified the company that its common stock has failed to meet the $1.00 per share Minimum Bid Price Requirement for the last 30 consecutive business days, putting its Nasdaq Capital Market listing at risk under Nasdaq Listing Rule 5550(a)(2).
BioCardia has an initial 180-day grace period, until February 16, 2027, to regain compliance by having a closing bid of at least $1.00 for at least ten consecutive business days. The notice does not immediately affect trading. If still noncompliant, BioCardia may seek an additional 180 days, potentially including a reverse stock split, and could appeal any delisting determination.
BioCardia, Inc. (BCDA) reported that its President and CEO, Peter Altman, purchased 5,400 shares of common stock on August 17, 2026 in an open-market or private transaction at a weighted average price of $0.93 per share. The trade was executed in multiple transactions between $0.92 and $0.97 per share, and Altman now directly holds 381,115 shares of BioCardia common stock. The filing indicates the transaction was not made pursuant to a Rule 10b5-1 trading plan.
BioCardia, Inc. director and President & CEO Peter Altman purchased 1,900 shares of common stock on August 13, 2026 in an open-market transaction at a weighted average price of $0.92 per share, with individual trade prices ranging from $0.89 to $0.95. Following this purchase, he directly holds 375,785 shares of BioCardia common stock. The transaction was not reported as made under a Rule 10b5-1 trading plan.
BioCardia, Inc. reported second quarter 2026 results highlighting supportive regulatory feedback and a narrower loss. Japan’s PMDA indicated it supports a regulatory submission for CardiAMP Cell Therapy for ischemic heart failure, the FDA indicated the CardiAMP HF II trial may be sufficient for U.S. approval, and the FDA also said DeNovo approval of the Helix transendocardial delivery catheter is possible. The company is preparing a PMDA submission for the fourth quarter, continues enrolling the CardiAMP HF II trial, and is awaiting FDA minutes on the Helix DeNovo pre-submission.
For the quarter ended June 30, 2026, net loss was $1.6 million compared with $2.0 million a year earlier, with net loss per share of $0.13 versus $0.40. Research and development expenses were $0.9 million and selling, general and administrative expenses were $0.7 million. For the first six months of 2026, net loss was $3.9 million versus $4.8 million. As of June 30, 2026, cash and cash equivalents were $4.1 million and total stockholders’ equity was $2.7 million.
BioCardia, Inc. reported a smaller net loss while strengthening its balance sheet but continues to face severe funding risk. For the six months ended June 30, 2026, net loss was $3.9 million compared with $4.8 million a year earlier, as research and development expenses declined to $2.1 million from $2.9 million with the CardiAMP Heart Failure Trial winding down. Selling, general and administrative costs stayed roughly flat at $1.8 million.
Cash and cash equivalents increased to $4.1 million from $2.5 million at year-end 2025, driven by $5.3 million in gross proceeds from at-the-market stock sales in the first half of 2026. Stockholders’ equity improved to $2.7 million. Management nonetheless states there is substantial doubt about the company’s ability to continue as a going concern beyond January 2027 without additional capital. Operationally, BioCardia highlights regulatory momentum: Japan’s PMDA feedback supports a CardiAMP submission in ischemic heart failure, and FDA minutes indicate the ongoing CardiAMP Heart Failure II trial may support Premarket Approval. Early CardiAMP chronic myocardial ischemia data and progress on the CardiALLO and Heart3D platforms are also described.
BioCardia, Inc. reports that President and CEO Peter Altman purchased 5,000 shares of common stock on July 29, 2026 at a weighted average price of $0.78 per share, executed in multiple trades between $0.77 and $0.80. Following this transaction, he directly holds 373,885 shares.
BioCardia, Inc. director and President & CEO Peter Altman purchased 500 shares of Common Stock on July 17, 2026 at $0.83 per share in an open-market transaction. After this trade, he directly owns 368,885 shares of BioCardia common stock.
The filing’s Rule 10b5-1 trading-plan checkbox was not selected.
BioCardia, Inc. President and CEO Peter Altman reported open-market purchases of company common stock. He bought 2,800 shares at $0.88 on July 14, 2026 and 1,500 shares at $0.86 on July 15, 2026, bringing his direct holdings to 368,385 shares. The reported prices reflect weighted averages of multiple trades executed between $0.86 and $0.89 per share.
BioCardia, Inc. President and CEO Peter Altman reported a series of open‑market purchases of common stock. On July 8–10, 2026, he bought a total of 7,500 shares in three transactions, including 5,500 shares at $0.97, 1,000 shares at $0.90, and 1,000 shares at $0.94 per share. After these purchases, he directly owns 369,485 common shares. A footnote states that one transaction was executed in multiple trades between $0.92 and $1.05 per share and that the reported price is a weighted average, with full trade‑level details available upon request.
BioCardia, Inc. President and CEO Peter Altman reported an open-market purchase of 5,400 shares of Common Stock at a weighted average price of $0.9645 per share. Following this transaction, he directly owns 361,985 shares. The trades were executed in multiple lots between $0.92 and $1.05 per share.